BridgeBio

Patent cliffs & loss of exclusivity

BridgeBio Pharma is a commercial-stage, multi-product biopharmaceutical company in Palo Alto, California, listed on Nasdaq as BBIO. In its own words it "exists to develop transformative medicines for genetic conditions", and it describes itself as "organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases". It was founded in 2015 by Neil Kumar, who is chief executive. Two businesses have been spun out of it, BridgeBio Oncology Therapeutics and GondolaBio, in both of which it retains a minority equity interest.

Company

AngelList URLhttps://angel.co/company/bridgebio
Business ModelCommerce
CAGE Code8FVJ9
Legal NameBridgeBio Pharma, Inc.
Company Operating StatusActive
Crunchbase URLhttps://www.crunchbase.com/organization/bridgebio
Email format{first}.{last}
Facebook URLhttps://www.facebook.com/BridgeBio-Pharma-100543364785856/

1 upcoming patent cliff

DrugIngredientTypeCliff
  1. ATTRUBYACORAMIDIS HYDROCHLORIDESmall mol.Aug 2039

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.